Successful exit: Miltenyi Biotec acquires biosensor company lino Biotech

21-Mar-2023 - Switzerland

lino Biotech, a biosensor company and the world’s only provider of Focal Molography®, announced it has been acquired by Miltenyi Biotec, a global biotech company based in Germany, on February 22, 2023.

Unsplash/pixabay.com

Symbolic image

Since its founding in 2020, lino Biotech has made significant advances in developing new biosensors to facilitate quality control in bioprocessing, measuring viral load in cell & gene therapy manufacturing, and testing for off-target responses in living cells to support drug discovery.

Headquartered in Bergisch Gladbach, Miltenyi Biotec has been a global provider of products and services for biomedical research and cellular therapy for more than 30 years.

Under the terms of the transaction, Miltenyi Biotec will acquire 100% of the shares from the investors including Roche Venture Fund and High-Tech Gründerfonds (HTGF). The specific terms of the transaction were not disclosed. Brown Gibbons Lang & Company (BGL), acted as the exclusive financial advisor to lino Biotech.

"lino´s innovative biosensor platform and Miltenyi’s cell and gene therapy approaches offer exciting synergies to lower the cost and establish a new standard for potency assays", Dr. Mirko Stange, CEO of lino Biotech.

"The HTGF is very pleased that lino Biotech AG with its technically demanding project, which the HTGF III has advanced together with the founding team and Roche Venture, find its application within the German Mittelstand", Dr. Martin Pfister, Principal at High-Tech Gründerfonds.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Something is happening in the life science industry ...

This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.

See the theme worlds for related content

Topic world Gene therapy

Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.

View topic world

Topic world Gene therapy

Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.